
1. curr med res opin. 2010 oct;26(10):2449-55. doi: 10.1185/03007995.2010.518135.

burden uk secondary care rotavirus disease seasonal infections in
children.

morgan c(1), adlard n, carroll s, parvataneni l.

author information: 
(1)cardiff research consortium ltd, uk. rhys.pockett@capita.co.uk

objective: rotavirus common infection affecting children 5 years,
which leads significant disease burden. burden potentially
exacerbated seasonality rotavirus, particularly context the
seasonality common childhood infections. primary study objective was
to describe pattern burden seasonal infections amongst children 
5 years age particular attention placed rotavirus other
gastrointestinal infections.
methods: retrospective analysis routine inpatient data relating to
selected seasonal infections uk conducted 2001/02 2007/08 
using data capse healthcare knowledge systems (chks, england, northern
ireland wales) information services division (isd, scotland). admissions 
with selected diagnoses extracted based international classification of
diseases (icd)-10 coding. episodes processed using hrg grouper and
costs applied according nhs national tariff.
results: financial year 2007/08, total number admissions uk 
for children 5 years selected seasonal infections 64,879 of
which 32,126 admissions associated gastrointestinal infections
including rotavirus gastroenteritis (rvge). seasonal peaks gastrointestinal
infections rvge occurred spring quarter respiratory syncytial
virus (rsv) influenza winter quarter. admissions gastrointestinal 
infection including rvge accounted 35 003 bed days 9922 due rvge. the
total cost admissions involving diagnosis seasonal infection £56
million. this, estimated infections icd-10 classification 
of rotavirus represented cost £8.6 million.
conclusion: rotavirus contributes significant burden seasonal
infections place inpatient paediatric resources winter spring
months. study may limited issues clinical coding the
infrequency confirmatory microbiological testing real-world practice.
vaccination might considered means reducing clinical economic
burden particularly long-term effectiveness ease administration 
proven.

doi: 10.1185/03007995.2010.518135 
pmid: 20818925  [indexed medline]

